05/11/22 7:00 AMNasdaq : MDNA clinical trialMedicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11’s Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy MeetingMDNA11 selectively increased a sub-population of anti-tumor ICOS + CD8 T cells without enhancing proliferation of highly immune-suppressiveRHEA-AIneutral
05/02/22 8:00 AMNasdaq : MDNA clinical trialMedicenna Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 ABILITY StudyNK cell / Treg and CD8 + T cell / Treg ratios increased by 4.4-fold and 2.6 fold, respectively, at the 30 µg/kg dose,RHEA-AIneutral
04/27/22 7:00 AMNasdaq : MDNA conferencesMedicenna Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor ConferenceMedicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President and CEO and Elizabeth Williams, CFO of Medicenna, will attendRHEA-AIneutral
04/08/22 9:14 AMNasdaq : MDNA clinical trialMedicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual MeetingTreatment with anti-PD-1-IL-2 BiSKIT led to statistically significant improvements in tumor growthRHEA-AIpositive
04/08/22 9:10 AMNasdaq : MDNA clinical trialMedicenna Presents Preclinical Data Demonstrating Anti-Cancer Activity of a Long-Acting IL-13 Super-Antagonist at the AACR Annual MeetingAbility ofRHEA-AIneutral
03/10/22 7:00 AMNasdaq : MDNA conferencesMedicenna Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare ConferenceMedicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will present aRHEA-AIneutral
03/09/22 7:00 AMNasdaq : MDNA Medicenna Announces Upcoming Poster Presentations at the AACR Annual MeetingMedicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the publication of two abstracts that have been accepted for electronic poster presentations atRHEA-AIneutral
03/03/22 7:00 AMNasdaq : MDNA managementMedicenna Announces Appointment of Clinical Advisory Board and Dr. Kapil Dhingra as Strategic AdvisorMedicenna’s Clinical Advisory Board is comprised of thought leaders in immuno-oncology with experience in clinical development of Proleukin® and next generation IL-2 Dr. Dhingra has a track record of development and approval of cancer therapies and extensive board level expertise resulting inRHEA-AIvery positive
02/10/22 7:00 AMNasdaq : MDNA conferencesMedicenna to Participate in the 11th Annual SVB Leerink Global Healthcare ConferenceMedicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participateRHEA-AIneutral
02/09/22 7:00 AMNasdaq : MDNA earningsMedicenna Reports Third Quarter Fiscal 2022 Financial Results and Operational HighlightsFirstRHEA-AIpositive